DNA Quantification & COVID-19 Testing
Applied Biosystems 7500

Capacity and Technologies
Bode has five (5) ABI 7500 instruments and uses Quantifiler® Trio on the 7500 to determine the quantity and quality of each sample. Bode also uses the Quantifiler Trio kit as a male screening tool to identify the strongest or most probative male sample as well as to aid in the identification of samples that may be better suited for Y-STR analysis. Bode has validated thresholds for male screening and stop-at-quant for Quantifiler Trio with all four STR kits in use.

Direct-to-DNA Sexual Assault Kit Testing
Bode validated this kit for both quantification and Y-screening since 2014 and has successfully used it on over thirty (30) SAK projects using a male-screening, direct-to-DNA approach. Bode pioneered the direct-to-DNA male-screening approach in 2002 using an internally developed Y Marker Screening assay before any kits were commercially available and has more experience than any other private forensic laboratory in the United States. Following the use of the internally developed assay, Bode was also one of the first to implement the direct-to-DNA approach using commercially available quantification kits. Through the work on these early projects it was determined that the Y-chromosome marker screening technique was more successful than traditional serology in detecting foreign and male DNA in samples taken from the vaginal and external genitalia areas and dried secretions. Bode now uses the Quantifiler Trio kit for quantification and Y-screening.

Mitochondrial DNA Quantification - Coming Soon in Early 2021!
Bode is currently validating an in-house developed mitochondrial DNA quant (BodeQuant Mito) that will specifically determine the amount of mitochondrial DNA present in an extract and estimate the quality/level of degradation. This will allow for the ability to stop-at-quant using a mitochondrial DNA workflow and to determine whether a sample is best suited for STRs or mtDNA. This is unique, as there are no commercial vendors offering a mitochondrial rt-PCR DNA quant assay.

COVID-19 Testing - Bode-CARES
Bode has tested nearly 10,000 samples for SARS-CoV-2 to help keep our communities safer during this pandemic using a PCR based assay on the ABI 7500. The comprehensive Bode-CARES program includes collection, testing, and reporting which enables our clients to develop a collection program to meet their specific needs.

Answers with Confidence and Accuracy
866-263-3443 or 703-646-9740 • bode.service@bodetech.com • bodetech.com
Bode-CARES COVID-19 Testing

Turnkey Solution
In addition to providing collection materials and laboratory testing, Bode can deploy medical professionals to set-up, observe and manage onsite collections, provide a medical provider to authorize testing and review results and arrange transportation of the samples to the laboratory.

How Bode-CARES Works

Collection
Bode tests nasopharyngeal, oropharyngeal, or nasal (anterior nares) swabs collected on a nylon flocked swab transported in a universal transport media.

Collections can be either managed and observed by the client or observed by medical professionals supplied by Bode.

Submissions
Bode manages test requests and issue reports through secure software accessed through our secure patient portal. All personal identifying information (PII) and reports will be encrypted. The handling and security of the data is HIPAA compliant.

Bode-CARES testing must be authorized by a medical provider prior to submission. Tests may be submitted according to company or agency policies. Bode has the ability to offer the service of a medical provider if desired.

Lab Testing
Bode-CARES offers COVID-19 testing for approximately 1,000 specimens per day. Diagnostic results are evaluated and reported within approximately 48-72 hours of receiving the sample.

Bode can also expedite results to report in 24 hours (subject to availability).

Reports
All reports are delivered electronically through the patient portal directly to the individual patient. Patients are notified by email once the results are available.

A designated official or physician (i.e. HR Director or Medical Liaison) will receive a copy of each test.